Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Capital Expenditures (2021 - 2025)

Historic Capital Expenditures for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $597000.0.

  • Kiniksa Pharmaceuticals International's Capital Expenditures rose 249565.22% to $597000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 29338.52%. This contributed to the annual value of $277000.0 for FY2024, which is 11307.69% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Capital Expenditures stood at $597000.0, which was up 249565.22% from $239000.0 recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Capital Expenditures ranged from a high of $597000.0 in Q3 2025 and a low of -$32000.0 during Q4 2022
  • Its 5-year average for Capital Expenditures is $102764.7, with a median of $56000.0 in 2023.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Capital Expenditures tumbled by 11274.9% in 2022 and then soared by 249565.22% in 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Capital Expenditures (Quarter) stood at $251000.0 in 2021, then crashed by 112.75% to -$32000.0 in 2022, then skyrocketed by 275.0% to $56000.0 in 2023, then surged by 35.71% to $76000.0 in 2024, then surged by 685.53% to $597000.0 in 2025.
  • Its Capital Expenditures was $597000.0 in Q3 2025, compared to $239000.0 in Q2 2025 and $99000.0 in Q1 2025.